GlassScriptPhysician profile
Teri M Oneil
NPI 1528241585
$16,861.32
in general payments reported to CMS, 2019-2025
44 companies · $885 in 2025
The $885 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,743 · 2022: $11K · 2023: $1,184 · 2024: $925 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $8,825.37 | 2022 | |
| Abbvie INC. | $1,220.85 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $830.85 | 2021-2022 | |
| Novo Nordisk INC | $630.89 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.03 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $279.75 | 2022-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $279.42 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $275.41 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Gilead Sciences, INC. | $242.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $216.45 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $198.28 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $194.74 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $191.71 | 2021-2022 | |
| Coloplast Corp | $189.11 | 2023-2025 | Titan |
| Alexion Pharmaceuticals, INC. | $170.93 | 2022-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Oneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.